{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:22:42Z","timestamp":1790140962805,"version":"4.0.1"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2025,11,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Drug-resistant tuberculosis (TB) remains a primary global health concern. Multidrug-resistant TB is defined by resistance to at least rifampicin (RIF) and isoniazid (INH), the two key drugs used in TB treatment. The BD MAX Multi-Drug Resistant Tuberculosis (BD MAX) assay is a fully automated real-time PCR platform recommended by the World Health Organization for the initial diagnosis of TB and RIF and INH resistance (RIF-R and INH-R) directly from pulmonary clinical samples. This study aimed to assess the off-label performance of BD MAX in clinical\n                      <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                      complex (MTBC) isolates under routine laboratory conditions. The assay was first validated using non-tuberculous mycobacteria (NTM) and MTBC isolates with known mutations. For real-world validation, it was compared to the GenoType MTBDR\n                      <jats:italic toggle=\"yes\">plus<\/jats:italic>\n                      by testing 1,440 clinical isolates prospectively. The BD MAX assay correctly excluded MTBC from all NTM cultures. Among MTBC isolates with known mutations, it identified 19 of 20 RIF-R isolates and 14 of 15 INH-R isolates. In prospective testing, BD MAX achieved 99.6% sensitivity (1,403\/1,409), 96.8% specificity (30\/31), and 99.5% overall accuracy (1,433\/1,440) for MTBC detection. For drug resistance detection, it showed 95.2% (40\/42) concordance for RIF, 96.8% (30\/31) for INH, and 81.3% (13\/16) for MDR when compared to MTBDR\n                      <jats:italic toggle=\"yes\">plus<\/jats:italic>\n                      . Discrepancies between MTBDR\n                      <jats:italic toggle=\"yes\">plus<\/jats:italic>\n                      and BD MAX included heteroresistant cases and unreportable resistance results by BD MAX due to infrequent mutations or low bacterial load. Overall, this study confirms BD MAX as an accurate and reliable tool for MTBC detection and drug resistance profiling in clinical isolates in high-volume TB laboratories.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        This study highlights the importance of the BD MAX Multi-Drug Resistant Tuberculosis assay (BD MAX) applied in clinical isolates for the detection of multidrug-resistant tuberculosis (MDR-TB), i.e.,\n                        <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                        resistance to rifampicin and isoniazid. TB is a global health issue, and drug-resistant TB makes treatment more difficult, favoring transmission and disease amplification. The BD MAX platform offers a faster and more automated way to detect TB and drug resistance. The study showed that BD MAX, applied off-label in clinical isolates, accurately identified TB and resistance to rifampicin and isoniazid, with results comparable to those of the widely used line probe assay. This is significant in a high-volume laboratory because it is more straightforward and more rapid than the line probe assay. BD MAX showed some limitations, especially in detecting rare mutations and in cases of low bacterial levels. Overall, this tool could improve TB care, especially in high-volume laboratories.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.00912-25","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:16:21Z","timestamp":1758633381000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of\n                    <i>Mycobacterium tuberculosis<\/i>\n                    clinical isolates in a high-volume reference laboratory"],"prefix":"10.1128","volume":"63","author":[{"given":"Angela Pires","family":"Brandao","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Instituto Oswaldo Cruz, Funda\u00e7\u00e3o Oswaldo Cruz (FIOCRUZ)","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiane Maria de Almeida","family":"Ferreira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Cristina dos Santos","family":"Simeao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilaine","family":"Ferrazoli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Chimara","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e2ngela Siqueira","family":"de Oliveira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-6688","authenticated-orcid":true,"given":"Juliana Maira Watanabe","family":"Pinhata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wna9e57","id-type":"ROR","asserted-by":"publisher"}],"name":"N\u00facleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization (WHO). 2024. Global tuberculosis report 2024 [Internet]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1"},{"key":"e_1_3_3_3_2","first-page":"56","volume-title":"Operational handbook on tuberculosis [Internet]. Module 3: Diagnosis Rapid diagnotics for tuberculosis diagnosis","author":"WHO","year":"2020","unstructured":"WHO. 2020. Operational handbook on tuberculosis [Internet]. Module 3: Diagnosis Rapid diagnotics for tuberculosis diagnosis, p 56. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/340256\/9789240022614-eng.pdf."},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization (WHO. 2023. Global Tuberculosis Report 2023 [Internet]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/373828\/9789240083851-eng.pdf?sequence=1"},{"key":"e_1_3_3_5_2","unstructured":"Minist\u00e9rio da Sa\u00fade. Brasil. 2024. Boletim Epidemiol\u00f3gico - Tuberculose 2024 [Internet]. Available from: https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/boletins-epidemiologicos\/2024\/boletim-epidemiologico-tuberculose-2024\/view"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2017.04.008"},{"key":"e_1_3_3_7_2","first-page":"81","volume-title":"Handbook on tuberculosis laboratory diagnostics methods in the european Union","author":"K\u00f6dm\u00f6n C","year":"2018","unstructured":"K\u00f6dm\u00f6n C. 2018. Handbook on tuberculosis laboratory diagnostics methods in the european Union, p 81\u201389. ECDC, Stockholm."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01582-19"},{"key":"e_1_3_3_9_2","unstructured":"World Health Organization. 2019. WHO evaluation of centralized assays for detection of TB and of resistance to rifampicin and isoniazid. Who [Internet]. Available from: http:\/\/www9.who.int\/tb\/features_archive\/centralized-assays-detection-tb\/en\/"},{"key":"e_1_3_3_10_2","first-page":"1","volume-title":"Manual e recomenda\u00e7\u00f5es para o diagn\u00f3stico laboratorial de tuberculose e micobact\u00e9rias n\u00e3o tuberculosas de interesse em sa\u00fade p\u00fablica no Brasil","author":"Minist\u00e9rio da Sa\u00fade","year":"2022","unstructured":"Minist\u00e9rio da Sa\u00fade. 2022. Manual e recomenda\u00e7\u00f5es para o diagn\u00f3stico laboratorial de tuberculose e micobact\u00e9rias n\u00e3o tuberculosas de interesse em sa\u00fade p\u00fablica no Brasil, p 1\u2013494. Minist\u00e9rio da Sa\u00fade - Secretaria de Vigil\u00e2ncia em Sa\u00fade."},{"key":"e_1_3_3_11_2","unstructured":"Becton Dickinson and Company. 2020. BD MAX MDR-TB Assay Package Insert. Available from: https:\/\/www.bd.com\/resource.aspx?IDX=35759"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-03847-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz932"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2020.06.013"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2024.0091"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2021.1997594"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2023.115925"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00146-8"},{"key":"e_1_3_3_19_2","unstructured":"Becton Dickinson and Company. 2019. BD MAX STR"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04316-0"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.07.036"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-8-48"},{"key":"e_1_3_3_23_2","unstructured":"World Health Organization. 2021. Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin rifabutin and rifapentine) [Internet]. Available from: https:\/\/www.who.int\/publications\/i\/item\/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine)"},{"key":"e_1_3_3_24_2","first-page":"1","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization (WHO)","year":"2023","unstructured":"World Health Organization (WHO). 2023. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed, p 1\u2013140","edition":"2"},{"key":"e_1_3_3_25_2","first-page":"9","article-title":"Practical issues in calculating the sample size for prevalence studies","volume":"1","author":"Naing L","year":"2006","unstructured":"Naing L, Winn T, Rusli BN. 2006. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 1:9\u201314.","journal-title":"Arch Orofac Sci"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000734"},{"key":"e_1_3_3_27_2","unstructured":"Minist\u00e9rio da Sa\u00fade. 2019. Manual de Recomenda\u00e7\u00f5es Para o Controle Da Tuberculose No Brasil. Minist\u00e9rio da Sa\u00fade. Available from: https:\/\/www.telelab.aids.gov.br\/index.php\/biblioteca-telelab\/item\/download\/172_d411f15deeb01f23d9a556619ae965c9"},{"key":"e_1_3_3_28_2","first-page":"1","article-title":"GenoType MTBDRplus VER 2.0 - molecular genetic assay for identification of the M. tuberculosis complex and its resistance to rifampicin and isoniazid from clinical specimens and cultivated samples","author":"Hain Lifescience","year":"2015","unstructured":"Hain Lifescience. 2015. GenoType MTBDRplus VER 2.0 - molecular genetic assay for identification of the M. tuberculosis complex and its resistance to rifampicin and isoniazid from clinical specimens and cultivated samples. Hain lifescience:1\u201310.","journal-title":"Hain lifescience"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001794"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2008.0798"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt090"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.9.3022-3024.1999"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1590\/1806-3713\/e20180128"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.10.023"},{"key":"e_1_3_3_35_2","unstructured":"U.S. Food and Drug Administration. 2007. Statistical guidance on reporting results from studies evaluating diagnostic tests - guidance for industry and FDA staff. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227215"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.31744\/einstein_journal\/2022AO5510"},{"key":"e_1_3_3_38_2","unstructured":"Minist\u00e9rio da Sa\u00fade. Brasil. 2021. Recomenda\u00e7\u00f5es para o diagn\u00f3stico e tratamento das doen\u00e7as causadas por micobact\u00e9rias n\u00e3o tuberculosas no Brasil. Available from: https:\/\/www.gov.br\/saude\/pt-br\/centrais-de-conteudo\/publicacoes\/svsa\/tuberculose\/recomendacoes-para-o-diagnostico-e-tratamento-das-doencas-causadas-por-micobacterias-nao-tuberculosas-no-brasil.pdf"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02168-20"},{"key":"e_1_3_3_40_2","volume-title":"Poster Presented at ECCMID 2018","author":"Zimmermann AS","year":"2018","unstructured":"Zimmermann AS, Dalpke A, Murray P, Paradis S, Cooper CK. 2018. Pre-Validation of the BD MAX MDR-TB * Assay for the Rapid Detection of MTBc DNA and Mutations Associated with Rifampin and Isoniazid Resistance P1561. Poster Presented at ECCMID 2018."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00912-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00912-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:02:30Z","timestamp":1762956150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00912-25"}},"subtitle":[],"editor":[{"given":"Melissa B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,12]]}},"alternative-id":["10.1128\/jcm.00912-25"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00912-25","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2025-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00912-25"}}